DOBUTamine

Pharmacologic Category

Adrenergic Agonist Agent; Inotrope

Dosing: Adult

Cardiac decompensation: IV infusion:

Initial dose: 0.5 to 1 mcg/kg/minute (per the manufacturer); may also initiate at higher doses (eg, 2.5 mcg/kg/minute) depending on severity of decompensation with titration to desired response (Leier 1977).

Maintenance dose: 2 to 20 mcg/kg/minute. Note: In patients with heart failure, lower doses are preferred to minimize adverse effects (ACCF/AHA [Yancy 2013]; AHA [van Diepen 2017]).

Maximum dose: 40 mcg/kg/minute. The ACCF/AHA 2013 heart failure guidelines recommend a maximum dose of 20 mcg/kg/minute (ACCF/AHA [Yancy 2013]).

Adult Advanced Cardiovascular Life Support (ACLS) guideline recommendation (in the immediate post-cardiac arrest care setting) (off-label use): IV infusion: Initial: 5 to 10 mcg/kg/minute; titrate to effect (AHA [Peberdy 2010])

Stress echocardiography (diagnostic agent) (off-label use): IV infusion: Initial: 5 to 10 mcg/kg/minute; increase at 3-minute intervals to 20 mcg/kg/minute, then 30 mcg/kg/minute, and then 40 mcg/kg/minute. May coadminister atropine in patients who do not achieve target heart rate (ASNC [Henzlova 2009]).

* See Dosage and Administration in AHFS Essentials for additional information.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer’s labeling.

Dosing: Pediatric

Hemodynamic support: Infants, Children, and Adolescents: Continuous IV or intraosseous infusion: Initial: 0.5 to 1 mcg/kg/minute, titrate gradually every few minutes until desired response achieved; usual range: 2 to 20 mcg/kg/minute (PALS [Kleinman 2010])

Dosing: Renal Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling.

Calculations

• Dobutamine

Use: Labeled Indications

Cardiac decompensation: Short-term management of patients with cardiac decompensation

Guideline recommendations:

Cardiogenic shock: The 2017 American Heart Association (AHA) scientific statement for the Contemporary Management of Cardiogenic Shock recommends dobutamine to maintain systemic perfusion and preserve end-organ performance in patients with cardiogenic shock. A vasopressor such as norepinephrine (preferred), vasopressin, or dopamine is typically the initial preferred therapy until hemodynamically stable. Once stable, consider adding or transitioning to an inotrope. However, an inotrope may be the preferred therapy for cardiogenic shock due to acute decompensated heart failure or in other cases when systolic blood pressure >90 mm Hg (ACCF/AHA [Yancy 2013]); AHA [van Diepen 2017]).

Inotropic support in advanced heart failure: Bridge therapy in stage D heart failure (HF) unresponsive to guideline-directed medical therapy and device therapy in patients awaiting heart transplant or mechanical circulatory support; short-term management of hospitalized patients with severe systolic dysfunction presenting with low blood pressure and significantly depressed cardiac output; long-term management (palliative therapy) in select patients with stage D HF unresponsive to guideline-directed medical therapy and device therapy who are not candidates for heart transplant or mechanical circulatory support (ACCF/AHA [Yancy 2013]).

* See Uses in AHFS Essentials for additional information.

Use: Off-Label: Adult

​Advanced life supportLevel of Evidence [G]

Based on the American Heart Association (AHA) guidelines for post cardiac arrest care in adults, the use of dobutamine during the post-resuscitation phase of cardiac arrest may be used for inotropic support.

​Myocardial dysfunction related to sepsis (positive inotropic agent)Level of Evidence [B, G]

Data from a number of clinical trials in patients with septic shock supports the use of dobutamine in the treatment of this condition Ref. Septic patients who have been adequately fluid resuscitated and have an adequate mean arterial pressure but low cardiac index (<2.5 L/minute/m2) may require dobutamine. Dobutamine may help reverse tissue hypoperfusion by increasing cardiac output.

Based on the Surviving Sepsis Campaign International Guidelines for the Management of Severe Sepsis and Septic Shock, a trial of dobutamine infusion may be given if persistent signs of hypoperfusion exist despite adequate intravascular volume repletion and use of vasopressor agents.

​Stress echocardiography (diagnostic agent)Level of Evidence [A, G]

Data from a number of clinical studies evaluating the use of dobutamine infusion during stress echocardiography for detecting coronary artery disease supports the use of dobutamine infusion as a diagnostic agent in patients who are incapable of physical exercise or who have contraindications (eg, bronchospastic airway disease) to pharmacologic vasodilator stressors. Wall motion abnormalities developing with increasing doses of dobutamine may help to identify ischemic and/or hibernating myocardium Ref.

Based on the American Society of Nuclear Cardiology, dobutamine infusion administered as a secondary pharmacologic stressor is an effective and recommended alternative agent to detect obstructive coronary disease.

Level of Evidence Definitions

​Level of Evidence Scale

Clinical Practice Guidelines

Bradycardia:

ACC/AHA/HRS, “Guideline on the Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay,” November 2018

Coronavirus Disease 2019 (COVID-19):

“Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19),” March 2020

Heart Failure:

ACCF/AHA, “2013 ACCF/AHA Guideline for the Management of Heart Failure,” June 2013

“HFSA 2010 Comprehensive Heart Failure Practice Guideline,” July 2010

Sepsis:

ACCM/SCCM, “Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients,” September 2004

“Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock,” February 2007

“Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016,” March 2017

Other:

AHA, “Post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,” November 2010

AHA, “Contemporary Management of Cardiogenic Shock,” September 2017

ASNC, “Imaging Guidelines for Nuclear Cardiology Procedures,” January 2009

Usual Infusion Concentrations: Pediatric

Note: Premixed solutions available.

IV infusion: 1,000 mcg/mL, 2,000 mcg/mL, or 4,000 mcg/mL

Usual Infusion Concentrations: Adult

Note: Premixed solutions available.

IV infusion: 250 mg in 500 mL (concentration: 500 mcg/mL), 500 mg in 250 mL (concentration: 2,000 mcg/mL), or 1,000 mg in 250 mL (concentration: 4000 mcg/mL) of D5W or NS

Administration: IV

Always administer via infusion device; administer into large vein.

Administration: Injectable Detail

pH: 2.5 to 5.5

Administration: Pediatric

Parenteral: Administer as a continuous IV infusion via an infusion device; administer into large vein.

Rate of infusion (mL/hour) = dose (mcg/kg/minute) x weight (kg) x 60 minutes/hour divided by the concentration (mcg/mL)

Storage/Stability

Premixed solution: Store at 20°C to 25°C (68°F to 77°F). Pink discoloration of solution indicates slight oxidation, but no significant loss of potency.

Vials: Store intact vials at 20°C to 25°C (68°F to 77°F). Following dilution in a compatible solution, use within 24 hours.

Preparation for Administration: Adult

Vials: Dilute 20 mL vial in ≥50 mL of a compatible IV solution; dilute 40 mL vial in ≥100 mL of a compatible IV solution. Maximum concentration: 5,000 mcg/mL (5 mg/mL).

Preparation for Administration: Pediatric

Parenteral: Dilute in D5W or NS to a maximum concentration of 5,000 mcg/mL (5 mg/mL); ISMP and Vermont Oxford Network recommends a standard concentration of 2,000 mcg/mL (2 mg/mL) for neonates (ISMP 2011)

Compatibility

See Trissel’s IV Compatibility Database

Open Trissel's IV Compatibility

Medication Patient Education with HCAHPS Considerations

What is this drug used for?

• It is used to help heart function in certain patients.

• It may be given to you for other reasons. Talk with the doctor.

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Shortness of breath

• Fast heartbeat

• Abnormal heartbeat

• Severe dizziness

• Passing out

• Vision changes

• Injection site pain or irritation

• Severe headache

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine's uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Medication Safety Issues

​Sound-alike/look-alike issues:

​High alert medication:

Contraindications

Hypersensitivity to dobutamine or sulfites (some contain sodium metabisulfate), or any component of the formulation; hypertrophic cardiomyopathy with outflow tract obstruction (formerly known as idiopathic hypertrophic subaortic stenosis [IHSS])

Note: When utilized for stress testing, additional contraindications according to the American Society of Nuclear Cardiology (ASNC) include patients with recent (<1 week) MI, unstable angina, severe aortic stenosis, atrial tachyarrhythmias with uncontrolled ventricular response, prior history of ventricular tachycardia, uncontrolled hypertension (>200/110 mm Hg), aortic dissection or large aortic aneurysm, and patients on beta blockers where heart rate and inotropic responses to dobutamine will be attenuated (ASNC [Henzlova 2009])

Warnings/Precautions

Concerns related to adverse effects:

• Arrhythmias: Ventricular arrhythmias, including nonsustained ventricular tachycardia and supraventricular arrhythmias, have been reported (Tisdale1995). Observe closely for arrhythmias in patients with acute heart failure; sudden cardiac death has been observed (O’Connor 1999; Pickworth 1992; Young 2000). Ensure that ventricular rate is controlled in atrial fibrillation/flutter before initiating; may increase ventricular response rate. In heart transplant candidates, institute appropriate measures to protect patient against risks of sudden cardiac death (Young 2000).

• Blood pressure effects: An increase in blood pressure is more common due to augmented cardiac output, but occasionally a patient may become hypotensive.

• Heart failure complications: An increased risk of hospitalization and death has been observed with prolonged use in New York Heart Association Class III/IV heart failure patients (O’Connor 1999).

• Tachycardia: May cause dose-related increases in heart rate.

• Ventricular ectopy: May exacerbate ventricular ectopy (dose-related).

Disease-related concerns:

• Aortic stenosis: Ineffective therapeutically in the presence of mechanical obstruction such as severe aortic stenosis.

• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy to minimize the risk of arrhythmias (ACC/AHA/ESC [Zipes 2006]; Tisdale 1995).

• Hypovolemia: If needed, correct hypovolemia first to optimize hemodynamics.

• Active myocardial ischemia/myocardial infarction (post): Use with caution in patients with active myocardial ischemia or recent myocardial infarction; can increase myocardial oxygen demand.

Concurrent drug therapy issues:

• Monoamine oxidase inhibitors (MAO-I): Use with extreme caution in patients taking MAO inhibitors; prolong hypertension may result from concurrent use.

Dosage form specific issues:

• Sodium sulfite: Product may contain sodium sulfite.

Special populations:

• Elderly: Use with caution in the elderly; start at lower end of the dosage range.

Other warnings/precautions:

• Long-term therapy: According to the ACCF/AHA 2013 heart failure guidelines, long-term use of intravenous inotropic therapy without a specific indication or for reasons other than palliation is potentially harmful (ACCF/AHA [Yancy 2013]).

* See Cautions in AHFS Essentials for additional information.

Geriatric Considerations

One study demonstrated beneficial hemodynamic effects in elderly patients; monitor closely.

Pregnancy Considerations

Dobutamine should not be used as a diagnostic agent for stress testing during pregnancy; use should be avoided when other options are available (ESC [Regitz-Zagrosek 2018]). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant female. Appropriate medications should not be withheld due to concerns of fetal teratogenicity. Dobutamine use during the post-resuscitation phase may be considered; however, the effects of inotropic support on the fetus should also be considered. Doses and indications should follow current Advanced Cardiovascular Life Support (ACLS) guidelines (AHA [Jeejeebhoy 2015 ]).

Breast-Feeding Considerations

It is not known if dobutamine is present in breast milk.

Briggs' Drugs in Pregnancy & Lactation

• Dobutamine

Adverse Reactions

1% to 10%:

Cardiovascular: Increased heart rate (10%), increased systolic blood pressure (8%), ventricular premature contractions (5%), angina pectoris (1% to 3%), chest pain (1% to 3%), palpitations (1% to 3%)

Central nervous system: Headache (1% to 3%)

Gastrointestinal: Nausea (1% to 3%)

Respiratory: Dyspnea (1% to 3%)

Frequency not defined:

Cardiovascular: Hypotension, ventricular ectopy

Endocrine & metabolic: Decreased serum potassium

<1%, postmarketing, and/or case reports: Cardiomyopathy (stress), eosinophilia, hypersensitivity reaction, localized phlebitis

* See Cautions in AHFS Essentials for additional information.

Toxicology

• Beta Agonists

Metabolism/Transport Effects

Substrate of COMT

Drug Interactions Open Interactions

AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Calcium Salts: May diminish the therapeutic effect of DOBUTamine. Risk C: Monitor therapy

Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics. Exceptions: Cannabidiol. Risk C: Monitor therapy

Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use. Risk D: Consider therapy modification

COMT Inhibitors: May increase the serum concentration of COMT Substrates. Risk C: Monitor therapy

Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. Risk C: Monitor therapy

Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics. Risk C: Monitor therapy

Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid. Specific dose adjustment recommendations are not presently available. Risk D: Consider therapy modification

Ozanimod: May enhance the hypertensive effect of Sympathomimetics. Management: Concomitant use of ozanimod with sympathomimetic agents is not recommended. If combined, monitor patients closely for the development of hypertension, including hypertensive crises. Risk D: Consider therapy modification

Procarbazine: May enhance the adverse/toxic effect of Sympathomimetics. Management: Consider alternatives to this combination when possible. Procarbazine prescribing information states that this combination should be avoided. Risk D: Consider therapy modification

Solriamfetol: Sympathomimetics may enhance the hypertensive effect of Solriamfetol. Sympathomimetics may enhance the tachycardic effect of Solriamfetol. Risk C: Monitor therapy

Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics. Risk C: Monitor therapy

Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics. Risk C: Monitor therapy

Monitoring Parameters

Blood pressure, ECG, heart rate, CVP, RAP, MAP; serum glucose, renal function; urine output; if pulmonary artery catheter is in place, monitor CI, PCWP, and SVR; ScvO2 or SvO2

Consult individual institutional policies and procedures.

Advanced Practitioners Physical Assessment/Monitoring

Assess risk vs benefit when using for stress testing in patients with recent MI, unstable angina, aortic stenosis, dissection or aneurysm, tachyarrhythmias, or patients on betablockers or if patient is taking MAO-Is. Monitor heart rhythm carefully, especially in patients with acute heart failure or heart transplant candidates.

Order BMP, renal function tests, EKG, and correct hypovolemia before administration.

Nursing Physical Assessment/Monitoring

Check ordered labs and report any abnormalities. Assess cardiac rhythm and blood pressure. Carefully monitor intake and output. Educate patient about fall prevention and caution patient to change positions slowly.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous, as hydrochloride:

Generic: 1 mg/mL (250 mL); 2 mg/mL (250 mL); 4 mg/mL (250 mL); 250 mg/20 mL (20 mL); 500 mg/40 mL (40 mL)

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous, as hydrochloride:

Generic: 12.5 mg/mL (20 mL)

Anatomic Therapeutic Chemical (ATC) Classification

• C01CA07

Generic Available (US)

Yes

Pricing: US

Solution (DOBUTamine in D5W Intravenous)

2 mg/mL (per mL): $0.06 - $0.17

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Mechanism of Action

Dobutamine, a racemic mixture, stimulates myocardial beta1-adrenergic receptors primarily by the (+) enantiomer and some alpha1 receptor agonism by the (-) enantiomer, resulting in increased contractility and heart rate, and stimulates both beta2- and alpha1-receptors in the vasculature. Although beta2 and alpha1 adrenergic receptors are also activated, the effects of beta2 receptor activation may equally offset or be slightly greater than the effects of alpha1 stimulation, resulting in some vasodilation in addition to the inotropic and chronotropic actions (Leier 1988; Majerus 1989; Ruffolo 1987). Lowers central venous pressure and wedge pressure, but has little effect on pulmonary vascular resistance (Leier 1977; Leier 1978).

Pharmacodynamics/Kinetics

Onset of action: IV: 1 to 10 minutes

Peak effect: 10 to 20 minutes

Metabolism: In tissues and hepatically to inactive metabolites

Half-life elimination: 2 minutes

Excretion: Urine (as metabolites)

Local Anesthetic/Vasoconstrictor Precautions

No information available to require special precautions

Effects on Dental Treatment

No significant effects or complications reported

Effects on Bleeding

No information available to require special precautions

Related Information

• Vasoactive Agents, Intravenous

Index Terms

Dobutamine HCl; Dobutamine HCl/D5W; Dobutamine Hydrochloride

FDA Approval Date

July 18, 1978

References

Bax JJ, Poldermans D, Elhendy A, et al, “Improvement of Left Ventricular Ejection Fraction, Heart Failure Symptoms and Prognosis After Revascularization in Patients With Chronic Coronary Artery Disease and Viable Myocardium Detected by Dobutamine Stress Echocardiography,” J Am Coll Cardiol, 1999, 34(1):163-9.[PubMed 10400006]

Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: an evidence-based review. Crit Care Med. 2004;32(11 Suppl):S455-465[PubMed 15542956]

Brierley J, Carcillo JA, Choong K, et al, “Clinical Practice Parameters for Hemodynamic Support of Pediatric and Neonatal Septic Shock: 2007 Update from the American College of Critical Care Medicine,” Crit Care Med, 2009, 37(2):666-88.[PubMed 19325359]

De Backer D, Berré J, Zhang H, Kahn RJ, Vincent JL. Relationship between oxygen uptake and oxygen delivery in septic patients: effects of prostacyclin versus dobutamine. Crit Care Med. 1993;21(11):1658-1664.[PubMed 8222681]

De Backer D, Moraine JJ, Berre J, Kahn RJ, Vincent JL. Effects of dobutamine on oxygen consumption in septic patients. Direct versus indirect determinations. Am J Respir Crit Care Med. 1994;150(1):95-100.[PubMed 8025780]

Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580-637.[PubMed 23353941]

Dobutamine in 5% dextrose injection [prescribing information]. Lake Forest, IL: Hospira, Inc; June 2019.

Dobutamine injection [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; March 2019.

Dobutamine injection [prescribing information]. Lake Forest, IL: Hospira, Inc; May 2018.

Fragasso G, Lu C, Dabrowski P, Pagnotta P, Sheiban I, Chierchia SL. Comparison of stress/rest myocardial perfusion tomography, dipyridamole and dobutamine stress echocardiography for the detection of coronary disease in hypertensive patients with chest pain and positive exercise test. J Am Coll Cardiol. 1999;34(2):441-447.[PubMed 10440157]

Gutierrez G, Clark C, Brown SD, Price K, Ortiz L, Nelson C. Effect of dobutamine on oxygen consumption and gastric mucosal pH in septic patients. Am J Respir Crit Care Med. 1994;150(2):324-329.[PubMed 8049810]

Hegenbarth MA and American Academy of Pediatrics Committee on Drugs, "Preparing for Pediatric Emergencies: Drugs to Consider," Pediatrics, 2008, 121(2):433-43.[PubMed 18245435]

Henzlova MJ, Cerqueira MD, Mahmarian JJ, Yao SS; Quality Assurance Committee of the American Society of Nuclear Cardiology. Stress protocols and tracers. J Nucl Cardiol. 2006;13(6):e80-e90.[PubMed 17174798]

Hollenberg SM, Ahrens TS, Annane D, et al, “Practice Parameters for Hemodynamic Support of Sepsis in Adult Patients: 2004 Update,” Crit Care Med, 2004, 32(9):1928-48.[PubMed 15343024]

Institute for Safe Medication Practice (ISMP) and Vermont Oxford Network, “Standard Concentrations of Neonatal Drug Infusions,” 2011. Available at https://www.ismp.org/Tools/PediatricConcentrations.pdf

Jardin F, Sportiche M, Bazin M, Bourokba A, Margairaz A. Dobutamine: a hemodynamic evaluation in human septic shock. Crit Care Med. 1981;9(4):329-332.[PubMed 7214944]

Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. Circulation. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.[PubMed 26443610]

Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18 Suppl 3):S876-908.[PubMed 20956230]

Leier CV. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. Am J Cardiol. 1988;62(8):86E-93E.[PubMed 2901217]

Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative systemic and regional hemodynamic effects of dopamine and dobutamine in patients with cardiomyopathic heart failure. Circulation. 1978;58(3 Pt 1):466-475.[PubMed 679437]

Leier CV, Webel J, Bush CA. The cardiovascular effects of the continuous infusion of dobutamine in patients with severe cardiac failure. Circulation. 1977;56(3):468-472.[PubMed 884803]

Leier CV. Regional blood flow responses to vasodilators and inotropes in congestive heart failure. Am J Cardiol. 1988;62(8):86E-93E.[PubMed 2901217]

Lindenfeld J, Albert NM, Boehmer JP, et al, “HFSA 2010 Comprehensive Heart Failure Practice Guideline,” J Card Fail, 2010, 16(6):e1-194.[PubMed 20610207]

Majerus TC, Dasta JF, Bauman JL, Danziger LH, Ruffolo RR Jr. Dobutamine: ten years later. Pharmacotherapy. 1989;9(4):245-59.[PubMed 2671957]

Marcovitz PA, Armstrong WF. Accuracy of dobutamine stress echocardiography in detecting coronary artery disease. Am J Cardiol. 1992;69(16):1269-1273.[PubMed 1585858]

Martin C, Saux P, Eon B, Aknin P, Gouin F. Septic shock: a goal-directed therapy using volume loading, dobutamine and/or norepinephrine. Acta Anaesthesiol Scand. 1990;34(5):413-417.[PubMed 2389659]

O'Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J. 1999;138(1 pt 1):78-86.[PubMed 10385768]

Patel MB, Kaplan IV, Patni RN, et al, “Sustained Improvement in Flow-Mediated Vasodilation After Short-Term Administration of Dobutamine in Patients With Severe Congestive Heart Failure,” Circulation, 1999, 99(1):60-4.[PubMed 9884380]

Paulman PM, Cantral K, Meade JG, et al, “Dobutamine Overdose,” JAMA, 1990, 264(18):2386-7.[PubMed 2231992]

Peberdy MA, Callaway CW, Neumar RW, et al; American Heart Association. Part 9: post-cardiac arrest care: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation. 2010;122(18)(suppl 3):S768-S786.[PubMed 20956225]

Phillips MS, “Standardizing I.V. Infusion Concentrations: National Survey Results,” Am J Health Syst Pharm, 2011, 68(22):2176-82.[PubMed 22058104]

Pickworth KK. Long-term dobutamine therapy for refractory congestive heart failure. Clin Pharm. 1992;11(7):618-624.[PubMed 1617912]

Previtali M, Lanzarini L, Ferrario M, et al. Dobutamine versus dipyridamole echocardiography in coronary artery disease. Circulation. 1991;83(5)(suppl):III27-III31.[PubMed 2022044]

Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165-3241. doi: 10.1093/eurheartj/ehy340.[PubMed 30165544]

Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med. 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6.[PubMed 28101605]

Rich MN, Woods WL, Davila-Roman VG, et al, “A Randomized Comparison of Intravenous Amrinone Versus Dobutamine in Older Patients With Decompensated Congestive Heart Failure,” J Am Geriatr Soc, 1995, 43(3):271-4.[PubMed 7884117]

Rivers E, Nguyen B, Havstad S, et al, “Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock," N Engl J Med, 2001, 345(19):1368-77.[PubMed 11794169]

Ruffolo RR Jr. The pharmacology of dobutamine. Am J Med Sci.1987;294(4):244-248.[PubMed 3310640]

Subhedar NV, "Treatment of Hypotension in Newborns," Semin Neonatolt, 2003, 8(6):413-23.[PubMed 15001113]

Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis. 1995;38(2):167-180.[PubMed 7568905]

Vallet B, Chopin C, Curtis SE, et al. Prognostic value of the dobutamine test in patients with sepsis syndrome and normal lactate values: a prospective, multicenter study. Crit Care Med. 1993;21(12):1868-1875.[PubMed 8252892]

van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. Circulation. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525.[PubMed 28923988]

Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.[PubMed 23741058]

Young JB, Moen EK. Outpatient parenteral inotropic therapy for advanced heart failure. J Heart Lung Transplant. 2000;19(8)(suppl):S49-S57.[PubMed 11016488]

Zipes DP, Camm AJ, Borggrefe M, et al; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(10):e385-e484.[PubMed 16935995]

Brand Names: International

Anchang (CN); Butamine (IL); Cardiject (ID, IN, TH, ZA); Cardomin (BD, LK, PH); Dasomin (PT); Dexdobu (VN); Dobamin (KR); Dobtan (BR); Dobu-Hameln (PE); Dobucard (MY, PH); Dobuject (AE, BH, CR, CZ, DK, DO, EG, FI, GT, HN, ID, JO, KR, MX, NI, NZ, PA, PH, PK, PL, QA, RU, SA, SE, SV, TW); Dobumin (BD); Dobunex (PH); Doburan (KR, PH, VE); Dobusafe (CO, VN); Dobutamin Hexal (DE, HU); Dobutamin-Ratiopharm (DE); Dobutamine Aguettant (FR); Dobutamine Hydrochloride (GB); Dobutamine Panpharma (FR); Dobutariston (BR); Dobutel (HK, PH, TH); Dobutina (PT); Dobutrex (AU, BD, BE, BF, BG, BJ, BR, CH, CI, CR, CZ, DK, DO, EG, ET, FR, GB, GH, GM, GN, GT, HN, HR, HU, IE, IN, JO, KE, KR, LR, MA, ML, MR, MU, MW, MX, MY, NE, NG, NI, PA, PY, RU, SA, SC, SD, SE, SI, SL, SN, SV, TN, TR, TZ, UG, VN, ZM, ZW); Dominic (ID); Doxa (PY); Dubutrex (JP); Duvig (AR); Easydobu (TW); Gendobu (TW); Inomin (BD); Inotop (AT); Inotrex (GR); Inotrop (ID); Kang Li Tuo (CN); Myofast (CO); Posiject (GB, IE); Pusogard (PH); Utamine (TW)

Last Updated 8/28/20